UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2018
Commission File Number: 001-32001
Aptose Biosciences Inc.
(Translation of registrant’s name into English)
251 Consumers Road, Suite 1105
Toronto, Ontario M2J 4R3
Canada
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☐ Form 40-F ☑
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) ☐
DOCUMENTS FILED AS PART OF THIS FORM 6-K
| Exhibit |
Description | |
| 99.1 | Form of Common Share Purchase Agreement between Aptose Biosciences Inc. and Aspire Capital Fund, LLC | |
| 99.2 | Form of Registration Rights Agreement between Aptose Biosciences Inc. and Aspire Capital Fund, LLC | |
| 99.3 | News release, dated May 31, 2018 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Aptose Biosciences Inc. | ||||||
| Date: May 31, 2018 | By: | /s/ Gregory Chow | ||||
| Name: | Gregory Chow | |||||
| Title: | Senior Vice President and Chief Financial Officer | |||||
2